Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:

Lundbeck To Market Teva's Azilect In Key Asian Countries

This article was originally published in PharmAsia News

  • News

Executive Summary

HONG KONG - Danish pharmaceutical company Lundbeck will sell Teva's Parkinson's disease drug Azilect in key Asian markets under a deal signed last week

You may also be interested in...



Lundbeck Steps Up Chinese Operations; Revises Lexapro Terms With J&J

Danish drug maker Lundbeck is increasing its sales force in China and revising its licensing agreement with partner Xian-Janssen - Johnson & Johnson's China subsidiary - to co-market its top-selling antidepressant Lexapro (escitalopram) in China

Lundbeck Steps Up Chinese Operations; Revises Lexapro Terms With J&J

Danish drug maker Lundbeck is increasing its sales force in China and revising its licensing agreement with partner Xian-Janssen - Johnson & Johnson's China subsidiary - to co-market its top-selling antidepressant Lexapro (escitalopram) in China

Mid-Tier Japanese Pharma See Flurry Of Licensing Activity Ahead Of Earnings Season

TOKYO - Japan's mid-tier pharma have had a fruitful week during and following the BioJapan partnering conference in Yokohama, announcing a number of deals with Japanese and Western biotechs as they continue to broaden their reach outside of Japan
Table

View full table

Related Content

Scrip
Tags:
UsernamePublicRestriction

Register

SC074416

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By